This content is machine translated Moderate to severe atopic dermatitis JAK inhibitor upadacitinib a clear winner in comparative study with dupilumab The development of innovative drugs for the treatment of atopic dermatitis (AD) is increasingly focused on targeted therapies that selectively interfere with disease-causing signaling pathways [1]. That the Janus kinase…
View Post 6 min This content is machine translated Chronic spontaneous urticaria (csU) Effectively treating wheals and angioedema – a practice-based update. The therapeutic goal of complete freedom from symptoms is realistic in many cases thanks to the treatment options available today. H1 antihistamines are still considered first-line therapy, and the use…
View Post 5 min This content is machine translated Psoriasis, Atopic Dermatitis, Urticaria “The big three” in dermatology In psoriasis as well as in atopic dermatitis and urticaria, the primary goal of treatment is to achieve symptom control and symptom relief, respectively. The therapy is stage-adapted. Because these…
View Post 4 min This content is machine translated Swiss Vaccination Plan 2021 Vaccination in chronic diseases – an update Vaccinations for other vaccine-preventable infections should not be neglected during the corona pandemic. Various congenital, disease-acquired, and iatrogenically induced conditions are associated with immune system suppression and therefore require consideration…
View Post 5 min This content is machine translated Moderate to severe atopic dermatitis Biologic therapy in the changing times: “Best practice” approaches in focus In addition to the new systemic drugs recently launched, several active substances are currently in development. These include some biologics in advanced stages of clinical testing. Overall, the future prospects…
View Post 4 min This content is machine translated Atopic dermatitis JAK inhibition as a mode of action – an update. Janus kinase (JAK) inhibitors are a promising new treatment option for adult patients with atopic eczema, given their rapid relief of pruritus and inflammatory lesions. In addition to baricitinib, which…
View Post 4 min This content is machine translated Allergic rhinitis Nose runs – research too Allergic rhinitis (AR) is one of the most common diseases in the world with an incidence of 10% to 40% in the population. Upper respiratory tract disease is manifested by…
View Post 12 min This content is machine translated Atopic dermatitis Digital support options for treatment The terms atopic dermatitis, atopic eczema and atopic dermatitis stand for a global skin disease, with children and adolescents being the most frequently affected. In 2020, a systematic review included… CME-Test
View Post 3 min This content is machine translated Phase IIa study Tocilizumab for the treatment of Schnitzler syndrome Schnitzler syndrome is a rare autoinflammatory disorder. Core symptoms include chronic, recurrent hives. In particular, for patients who do not respond to anti-IL1 therapy, there is a need for new…
View Post 5 min This content is machine translated Dust mite allergy Tiny components with a big impact Dust mite allergy is characterized by year-round symptoms of the nose, lungs and/or eyes. Inadequate diagnosis and treatment may favor the development of allergic asthma (“floor change”). If symptomatic therapy…
View Post 4 min This content is machine translated Sublingual immunotherapy New pill against the mite The past year has not brought much news in terms of large studies on sublingual immunotherapy (SLIT) that are suitable for approval. There were new findings, particularly on the effect…